These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2784908)

  • 21. Bone marrow transplantation in the rat. V. Lymphoid cell subclasses in the target organs during acute graft-versus-host disease.
    Renkonen R
    Transplantation; 1986 Jun; 41(6):704-8. PubMed ID: 2940737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
    Mazumder A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset.
    Xystrakis E; Bernard I; Dejean AS; Alsaati T; Druet P; Saoudi A
    Eur J Immunol; 2004 Feb; 34(2):408-17. PubMed ID: 14768045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
    J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.
    Via CS; Rus V; Gately MK; Finkelman FD
    J Immunol; 1994 Nov; 153(9):4040-7. PubMed ID: 7930611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antilymphocytic antibodies and marrow transplantation. IV. Comparison of the effects of antibody fragments directed against immunoglobulin or lymphocyte antigens on acute secondary disease.
    Rodt H; Therfelder S; Eulitz M
    Exp Hematol; 1974; 2(4):195-203. PubMed ID: 4156327
    [No Abstract]   [Full Text] [Related]  

  • 30. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular basis of graft-versus-host reactions.
    Clancy J
    Am J Anat; 1984 Jul; 170(3):491-9. PubMed ID: 6332523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FTY720, a novel immunosuppressant, possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats.
    Masubuchi Y; Kawaguchi T; Ohtsuki M; Suzuki C; Amano Y; Hoshino Y; Chiba K
    Transplant Proc; 1996 Apr; 28(2):1064-5. PubMed ID: 8623228
    [No Abstract]   [Full Text] [Related]  

  • 34. Graft versus host disease in rats made tolerant for organ allografts.
    Morrissey NJ; Blom D; Ryan C; Fisher T; Bronsther O; Orloff M
    J Surg Res; 1997 May; 69(2):307-15. PubMed ID: 9224398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones.
    Parkman R
    J Immunol; 1986 May; 136(10):3543-8. PubMed ID: 2871104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological profile of A85 4777, a novel antiinflammatory agent with nonclassical immunosuppressive properties.
    Bartlett RR; Schleyerbach R; Schorlemmer KU; Wolf E
    Transplant Proc; 1990 Aug; 22(4):1666-70. PubMed ID: 2389430
    [No Abstract]   [Full Text] [Related]  

  • 39. Recombinant interleukin-2 (IL-2) can reverse the blood transfusion effect.
    Dallman MJ; Wood KJ; Morris PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1165-7. PubMed ID: 2650086
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of natural killer cells in lethal graft-versus-host disease in rat models.
    Akioka K; Nakajima H; Fujiwara I; Mastuda T; Arakawa K; Oka T
    Transplant Proc; 1997; 29(1-2):722-4. PubMed ID: 9123498
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.